Viewing Study NCT03821168


Ignite Creation Date: 2025-12-24 @ 5:47 PM
Ignite Modification Date: 2025-12-25 @ 3:14 PM
Study NCT ID: NCT03821168
Status: UNKNOWN
Last Update Posted: 2019-02-05
First Post: 2018-12-27
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema
Sponsor: Shahid Beheshti University of Medical Sciences
Organization:

Study Overview

Official Title: The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema
Status: UNKNOWN
Status Verified Date: 2018-12
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: after advent of RD photoreceptor degeneration Occurred. This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened .

Process of degeneration begins from first hours of RD establishment Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered in recent years .

How to stop this phenomena and neuroprotective agent role in this issue are a new interest of researches.

In the study investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study.
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: